<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364555</url>
  </required_header>
  <id_info>
    <org_study_id>LIKLO-1</org_study_id>
    <nct_id>NCT04364555</nct_id>
  </id_info>
  <brief_title>Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.</brief_title>
  <official_title>Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus. A Multicenter Placebo-controlled Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malmö University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Malmö University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to study the effect of clobetasol in symptomatic oral lichen planus. We will include
      90 patients and randomly separate them in three equal groups. The frist group will recive
      active treatment both morning an evening. Group two recieves palcebo in the morning and
      active treatment in the evening. Group three will get palcebo both in the morning and in the
      evening. All Groups will follow the same protocol with rinsing twice daily wth clobetasol in
      conjunction with antfungal treatment. The patients will be controlled after two weeks and and
      again after another two weeks. A biopsy will be performed at inclusion and another biopsy
      will be taken at the end of the testperiod. Smears for candida will also be evaluated. The
      patients will be examined for change in clinical apearance and will answer questions to note
      changes in symptoms. Our hypothesesis: #Patients recieving clobetasolrinses will have a
      better resolution af symptoms than those who got placebo. #Patients treated with clobetasol
      twice daily will have a faster relief of symptoms than patients just teated once daily. #The
      clinical signs of oral lichen planus will diminish more pronounced in the two groups given
      active treatment. #A majority of the OLP lesions were infected by candida. #Specific
      histological changes can be seen in the biopsies taken after clobetasoltreatment compared to
      those taken before treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical apearance of the lichen lesion</measure>
    <time_frame>Four weeks</time_frame>
    <description>Site-, severity- and activity-score acording to Escudier et al</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oral health impact profile</measure>
    <time_frame>Four weeks</time_frame>
    <description>Oral health impact profile (OHIP-14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Four weeks</time_frame>
    <description>VAS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burning sensation score</measure>
    <time_frame>Four weeks</time_frame>
    <description>VAS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological apearance</measure>
    <time_frame>Four weeks</time_frame>
    <description>Amount and degree of lichenoid reaction in biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Candida</measure>
    <time_frame>baseline (At treatment start)</time_frame>
    <description>Candida hyfes in smear from lichenlesions</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Active/active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The bottle for use in the morning cantains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken oraly 1ml 4 times daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol Propionate</intervention_name>
    <description>Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.</description>
    <arm_group_label>Active/active</arm_group_label>
    <other_name>Klobetasol APL oral gel 0.025%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/active</intervention_name>
    <description>Placebo/active</description>
    <arm_group_label>Placebo/active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo/placebo</intervention_name>
    <description>Placebo/placebo</description>
    <arm_group_label>Placebo/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic oral lichen planus

          -  Age above 40 years

        Exclusion Criteria:

          -  Lichenoid contactlesions

          -  Graft versus host disease

          -  Bacteriarelated lichenoid reaction

          -  Intraoral vesiculobulous diseases

          -  Active antbiotic treatment

          -  Active treatment with steroids or other immunomodelling substance

          -  Alergy to Clobetasol

          -  Severe periodontitis

          -  Bad oral hygiene

          -  Biopsy not supporting OLP

          -  Alergy to nystatin

          -  Not in menopaus

          -  Previous or actual oral malignancy

          -  Participation in other medical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bengt Götrick, Docent</last_name>
    <role>Study Chair</role>
    <affiliation>Malmö University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fredrik Gränse, DDS</last_name>
    <phone>0046736954499</phone>
    <email>fredrik.granse@mau.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bengt Götrick, Docent</last_name>
    <phone>0046406658427</phone>
    <email>bengt.gotrick@mau.se</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Malmö University</investigator_affiliation>
    <investigator_full_name>Fredrik Gränse</investigator_full_name>
    <investigator_title>Dentist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Still undecided since we dont know what data to share and how, yet.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

